BioCentury | May 19, 2017
Clinical News

FDA agrees with Argos' decision to continue Phase III of rocapuldencel-T

...PFS), objective response rate (ORR), disease control rate (DCR) and safety. In 2015, Argos granted Chongqing Lummy Pharmaceutical Co. Ltd....
...for oncology indications (see BioCentury, April 20, 2015 ). Argos Therapeutics Inc. (NASDAQ:ARGS), Durham, N.C. Chongqing Lummy Pharmaceutical Co. Ltd....
...ORR), disease control rate (DCR) and safety Status: Phase III ongoing Milestone: NA Julian Zhu AGS-003 rocapuldencel-T Argos Therapeutics Inc. Chongqing Lummy Pharmaceutical Co. Ltd....
BioCentury | Apr 21, 2017
Clinical News

Rocapuldencel-T: Additional Ph III ADAPT data

...cash and a 12-month operating loss of $52.3 million. Argos Therapeutics Inc. (NASDAQ:ARGS), Durham, N.C. Chongqing Lummy Pharmaceutical Co. Ltd....
...disease control rate (DCR) and safety Status: Additional Phase III data Milestone: NA Alex Himes AGS-003 rocapuldencel-T Argos Therapeutics Inc. Chongqing Lummy Pharmaceutical Co. Ltd....
BioCentury | Feb 24, 2017
Clinical News

Rocapuldencel-T: Ph III ADAPT data

...to $60 million (see BioCentury, June 20, 2016 ). Argos Therapeutics Inc. (NASDAQ:ARGS), Durham, N.C. Chongqing Lummy Pharmaceutical Co. Ltd....
...survival (PFS), tumor response and safety Status: Phase III data Milestone: NA Jaime De Leon AGS-003 rocapuldencel-T Argos Therapeutics Inc. Chongqing Lummy Pharmaceutical Co. Ltd....
BioCentury | Feb 22, 2017
Clinical News

Argos plummets on futility analysis of rocapuldencel-T for RCC

...Phase II trials as neoadjuvant therapy for RCC and bladder cancer. In 2015, Argos granted Chongqing Lummy Pharmaceutical Co. Ltd....
...NYSE:PFE) markets Sutent, a small molecule that inhibits multiple receptor tyrosine kinases. Jaime De Leon AGS-003 rocapuldencel-T Argos Therapeutics Inc. Chongqing Lummy Pharmaceutical Co. Ltd....
BioCentury | Jul 11, 2016
Financial News

Argos completes private placement of common stock and warrants

...5.5 million Price: $5.44 Shares after offering: 29.9 million Investors: Pharmstandard International S.A.; Forargos B.V.; Chongqing Lummy Pharmaceutical Co. Ltd....
BioCentury | Mar 14, 2016
Financial News

Argos completes private placement of common stock and warrants

...3.7 million Price: $5.44 Shares after offering: 24.4 million Investors: Pharmstandard International S.A.; Forargos B.V.; Chongqing Lummy Pharmaceutical Co. Ltd....
BioCentury | Jan 11, 2016
Finance

Sowing season

...Inc. (NASDAQ:APRI) Vitaros alprostadil Erectile dysfunction (ED) Resubmit NDA 2H16 Argos Therapeutics Inc. (NASDAQ:ARGS) / Chongqing Lummy Pharmaceutical Co. Ltd....
BioCentury | Jun 22, 2015
Finance

Strategic investing in China

...how to market in China." TVM announced a $50 million first close in April with Chongqing Lummy Pharmaceutical Co. Ltd....
BioCentury | Apr 20, 2015
Company News

Argos, Chongqing Lummy Pharmaceutical deal

...in additional regulatory and commercial milestones, plus double-digit royalties. Argos Therapeutics Inc. (NASDAQ:ARGS), Durham, N.C. Chongqing Lummy Pharmaceutical Co. Ltd....
BioCentury | Apr 20, 2015
Financial News

TVM Capital financial update

...$50 million for its China BioPharma Capital I fund. The fund includes an investment from Chongqing Lummy Pharmaceutical Co. Ltd....
Items per page:
1 - 10 of 12
BioCentury | May 19, 2017
Clinical News

FDA agrees with Argos' decision to continue Phase III of rocapuldencel-T

...PFS), objective response rate (ORR), disease control rate (DCR) and safety. In 2015, Argos granted Chongqing Lummy Pharmaceutical Co. Ltd....
...for oncology indications (see BioCentury, April 20, 2015 ). Argos Therapeutics Inc. (NASDAQ:ARGS), Durham, N.C. Chongqing Lummy Pharmaceutical Co. Ltd....
...ORR), disease control rate (DCR) and safety Status: Phase III ongoing Milestone: NA Julian Zhu AGS-003 rocapuldencel-T Argos Therapeutics Inc. Chongqing Lummy Pharmaceutical Co. Ltd....
BioCentury | Apr 21, 2017
Clinical News

Rocapuldencel-T: Additional Ph III ADAPT data

...cash and a 12-month operating loss of $52.3 million. Argos Therapeutics Inc. (NASDAQ:ARGS), Durham, N.C. Chongqing Lummy Pharmaceutical Co. Ltd....
...disease control rate (DCR) and safety Status: Additional Phase III data Milestone: NA Alex Himes AGS-003 rocapuldencel-T Argos Therapeutics Inc. Chongqing Lummy Pharmaceutical Co. Ltd....
BioCentury | Feb 24, 2017
Clinical News

Rocapuldencel-T: Ph III ADAPT data

...to $60 million (see BioCentury, June 20, 2016 ). Argos Therapeutics Inc. (NASDAQ:ARGS), Durham, N.C. Chongqing Lummy Pharmaceutical Co. Ltd....
...survival (PFS), tumor response and safety Status: Phase III data Milestone: NA Jaime De Leon AGS-003 rocapuldencel-T Argos Therapeutics Inc. Chongqing Lummy Pharmaceutical Co. Ltd....
BioCentury | Feb 22, 2017
Clinical News

Argos plummets on futility analysis of rocapuldencel-T for RCC

...Phase II trials as neoadjuvant therapy for RCC and bladder cancer. In 2015, Argos granted Chongqing Lummy Pharmaceutical Co. Ltd....
...NYSE:PFE) markets Sutent, a small molecule that inhibits multiple receptor tyrosine kinases. Jaime De Leon AGS-003 rocapuldencel-T Argos Therapeutics Inc. Chongqing Lummy Pharmaceutical Co. Ltd....
BioCentury | Jul 11, 2016
Financial News

Argos completes private placement of common stock and warrants

...5.5 million Price: $5.44 Shares after offering: 29.9 million Investors: Pharmstandard International S.A.; Forargos B.V.; Chongqing Lummy Pharmaceutical Co. Ltd....
BioCentury | Mar 14, 2016
Financial News

Argos completes private placement of common stock and warrants

...3.7 million Price: $5.44 Shares after offering: 24.4 million Investors: Pharmstandard International S.A.; Forargos B.V.; Chongqing Lummy Pharmaceutical Co. Ltd....
BioCentury | Jan 11, 2016
Finance

Sowing season

...Inc. (NASDAQ:APRI) Vitaros alprostadil Erectile dysfunction (ED) Resubmit NDA 2H16 Argos Therapeutics Inc. (NASDAQ:ARGS) / Chongqing Lummy Pharmaceutical Co. Ltd....
BioCentury | Jun 22, 2015
Finance

Strategic investing in China

...how to market in China." TVM announced a $50 million first close in April with Chongqing Lummy Pharmaceutical Co. Ltd....
BioCentury | Apr 20, 2015
Company News

Argos, Chongqing Lummy Pharmaceutical deal

...in additional regulatory and commercial milestones, plus double-digit royalties. Argos Therapeutics Inc. (NASDAQ:ARGS), Durham, N.C. Chongqing Lummy Pharmaceutical Co. Ltd....
BioCentury | Apr 20, 2015
Financial News

TVM Capital financial update

...$50 million for its China BioPharma Capital I fund. The fund includes an investment from Chongqing Lummy Pharmaceutical Co. Ltd....
Items per page:
1 - 10 of 12